Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAN PIERRE ZAUSNER SKARBNIK

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1366754954
CMS profile
914590
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$135,844.88

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAN PIERRE ZAUSNER SKARBNIK

NPI 1366754954 · CMS profile ID 914590

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ALAN PIERRE ZAUSNER SKARBNIK, NPI 1366754954, CMS profile ID 914590, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1366754954?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $135,844.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $125.0008/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843640261 CMS
JAZZ PHARMACEUTICALS INC. $2,940.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607843 CMS
BeiGene USA, Inc. $1,950.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696983 CMS
JAZZ PHARMACEUTICALS INC. $125.0007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607841 CMS
AstraZeneca Pharmaceuticals LP $4,450.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829467315 CMS
JAZZ PHARMACEUTICALS INC. $759.5007/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607839 CMS
AstraZeneca Pharmaceuticals LP $4,450.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829367005 CMS
AstraZeneca Pharmaceuticals LP $700.0807/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829549071 CMS
AstraZeneca Pharmaceuticals LP $124.9107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829718865 CMS
BeiGene USA, Inc. $1,950.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696985 CMS
AstraZeneca Pharmaceuticals LP $305.9207/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829498799 CMS
AstraZeneca Pharmaceuticals LP $70.3807/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829721359 CMS
AstraZeneca Pharmaceuticals LP $160.4607/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829757303 CMS
AstraZeneca Pharmaceuticals LP $118.9707/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829998935 CMS
AstraZeneca Pharmaceuticals LP $1,100.0007/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830104095 CMS
JAZZ PHARMACEUTICALS INC. $2,940.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607561 CMS
AstraZeneca Pharmaceuticals LP $300.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829586347 CMS
JAZZ PHARMACEUTICALS INC. $120.7806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607559 CMS
AbbVie Inc. $1,650.0006/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796302291 CMS
Pharmacyclics LLC, An AbbVie Company $16.9206/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016477 CMS
Pharmacyclics LLC, An AbbVie Company $20.0006/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016479 CMS
Pharmacyclics LLC, An AbbVie Company $149.8406/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016481 CMS
Pharmacyclics LLC, An AbbVie Company $150.1806/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016483 CMS
Pharmacyclics LLC, An AbbVie Company $347.9706/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016485 CMS
Pharmacyclics LLC, An AbbVie Company $529.0706/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016487 CMS
Pharmacyclics LLC, An AbbVie Company $4,100.0006/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016489 CMS
Janssen Biotech, Inc. $1,000.0005/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788162863 CMS
AstraZeneca Pharmaceuticals LP $3,885.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830093477 CMS
Janssen Biotech, Inc. $500.0005/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788162865 CMS
Pharmacyclics LLC, An AbbVie Company $82.0505/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016475 CMS
AstraZeneca Pharmaceuticals LP $2,800.0005/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829283107 CMS
AbbVie Inc. $825.0005/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796302289 CMS
AstraZeneca Pharmaceuticals LP $300.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829535189 CMS
BeiGene USA, Inc. $1,950.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696987 CMS
Pharmacyclics LLC, An AbbVie Company $2,200.0004/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781016473 CMS
AstraZeneca Pharmaceuticals LP $4,450.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829808011 CMS
AstraZeneca Pharmaceuticals LP $172.2804/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829333591 CMS
AstraZeneca Pharmaceuticals LP $236.2904/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829388317 CMS
AstraZeneca Pharmaceuticals LP $69.2104/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829649807 CMS
AstraZeneca Pharmaceuticals LP $119.8404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830084789 CMS
AstraZeneca Pharmaceuticals LP $4,450.0004/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829869611 CMS
AstraZeneca Pharmaceuticals LP $125.0004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829766623 CMS
AstraZeneca Pharmaceuticals LP $18.0504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829851323 CMS
AstraZeneca Pharmaceuticals LP $132.3004/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830035159 CMS
AstraZeneca Pharmaceuticals LP $174.2204/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830144425 CMS
AstraZeneca Pharmaceuticals LP $64.0204/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830145491 CMS
Secura Bio, Inc. $127.6004/08/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 851660973 CMS
Kite Pharma, Inc. $1,800.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844424145 CMS
Alexion Pharmaceuticals, Inc. $1,250.0003/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783119231 CMS
MorphoSys, US Inc. $1,217.5003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854734881 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $154,772.34 157
PY2020 $77,277.54 62
PY2021 $135,844.88 107
PY2022 $173,706.19 115
PY2023 $241,561.60 171
PY2024 $129,388.89 113
PY2025 $171,893.70 156

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,407.49 2
PY2025 Principal investigator $1,497,977.99 72
PY2024 Recipient $1,045.54 2
PY2024 Principal investigator $2,005,059.27 63
PY2023 Recipient $185,946.08 4
PY2023 Principal investigator $1,224,916.67 31
PY2022 Recipient $54,759.00 1
PY2022 Principal investigator $1,142,264.31 30
PY2021 Recipient $5,321.43 5
PY2021 Principal investigator $1,378,819.98 24
PY2020 Recipient $2,100.00 2
PY2020 Principal investigator $1,375,547.50 19
PY2019 Principal investigator $51,073.12 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies No dispute reported 06/30/2026 1202532648
Principal investigator 1 Kite Pharma, Inc. $1,630.00 12/16/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069979
Principal investigator 1 Kite Pharma, Inc. $3,000.00 12/16/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069984
Recipient F. Hoffmann-La Roche AG $977.45 12/12/2025 Covered Recipient Physician glofitamab atezo or glofitamab polatuzumab in R R NHL No dispute reported 06/30/2026 1211534256
Recipient F. Hoffmann-La Roche AG $430.04 12/08/2025 Covered Recipient Physician glofitamab atezo or glofitamab polatuzumab in R R NHL No dispute reported 06/30/2026 1211534252
Principal investigator 1 ABBVIE INC. $985.40 12/04/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418537
Principal investigator 1 AstraZeneca UK Limited $48,026.80 12/04/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma No dispute reported 06/30/2026 1185538745
Principal investigator 1 ABBVIE INC. $31,319.60 11/06/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202523407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $804.96 11/06/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223268824
Principal investigator 1 ABBVIE INC. $1,830.40 11/05/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202522483
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,383.00 11/05/2025 Non-covered Recipient Entity
Novant Health Clinical Research Llc
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1235995129
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,345.00 11/05/2025 Non-covered Recipient Entity
Novant Health Clinical Research Llc
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1235995131
Principal investigator 1 ABBVIE INC. $985.40 11/04/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418534
Principal investigator 1 ABBVIE INC. $18,989.10 10/23/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202518419
Principal investigator 1 ABBVIE INC. $650.00 10/21/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202517677
Principal investigator 1 Kite Pharma, Inc. $1,771.00 10/21/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069972
Principal investigator 1 Kite Pharma, Inc. $33,952.62 10/21/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069976
Principal investigator 1 ABBVIE INC. $52,760.50 10/16/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202517399
Principal investigator 1 ABBVIE INC. $1,550.90 10/09/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418530
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,950.00 10/07/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252498733
Principal investigator 1 Genentech, Inc. $1,305.00 10/06/2025 Non-covered Recipient Entity
PRESBYTERIAN HOSPITAL CANCER CENTER
glofitamab atezo or glofitamab polatuzumab in R R NHL No dispute reported 06/30/2026 1211638837
Principal investigator 1 Kite Pharma, Inc. $2,100.00 09/16/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069963
Principal investigator 1 Kite Pharma, Inc. $1,630.00 09/16/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069968
Principal investigator 1 ABBVIE INC. $1,000.00 09/11/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202418526
Principal investigator 1 Celgene Corporation $9,866.00 09/10/2025 Non-covered Recipient Entity
Novant Health Clinical Research Llc
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1222306553
Principal investigator 1 ABBVIE INC. $400.00 09/09/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202510342
Principal investigator 1 ABBVIE INC. $1,830.40 09/04/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202509796
Principal investigator 1 ABBVIE INC. $150.80 09/02/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202507101
Principal investigator 1 ABBVIE INC. $3,705.00 08/27/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202505963
Principal investigator 1 Kite Pharma, Inc. $1,630.00 08/19/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069959
Principal investigator 1 ABBVIE INC. $27,275.22 08/05/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202501098
Principal investigator 1 ABBVIE INC. $41,071.03 08/01/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202500912
Principal investigator 1 ABBVIE INC. $3,350.00 07/31/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202418524
Principal investigator 1 ABBVIE INC. $1,200.00 07/25/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202499888
Principal investigator 1 Kite Pharma, Inc. $1,771.00 07/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069955
Principal investigator 1 ABBVIE INC. $900.00 07/08/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202497304
Principal investigator 1 ABBVIE INC. $1,550.90 07/02/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418520
Principal investigator 1 ABBVIE INC. $1,830.40 07/02/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202495681
Principal investigator 1 ABBVIE INC. $1,550.90 06/03/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418514
Principal investigator 1 BeOne Medicines Ltd. $3,463.30 05/29/2025 Non-covered Recipient Entity
Novant Health Hematology - Charlotte
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190331457
Principal investigator 1 Kite Pharma, Inc. $1,630.00 05/20/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069951
Principal investigator 1 AstraZeneca UK Limited $5,430.80 05/14/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185538739
Principal investigator 1 BeiGene, Ltd. $2,903.00 05/02/2025 Non-covered Recipient Entity
Novant Health Hematology - Charlotte
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190322428
Principal investigator 1 ABBVIE INC. $1,700.00 04/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202478233
Principal investigator 1 ABBVIE INC. $1,127.10 04/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202478238
Principal investigator 1 Kite Pharma, Inc. $3,401.00 04/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069946
Principal investigator 1 ABBVIE INC. $2,609.75 04/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202468872
Principal investigator 1 ABBVIE INC. $4,288.70 04/02/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202468506
Principal investigator 1 ABBVIE INC. $1,750.00 03/27/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202418506
Principal investigator 1 Kite Pharma, Inc. $3,955.00 03/18/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069942
Principal investigator 1 ABBVIE INC. $1,579.50 03/07/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418502
Principal investigator 1 ABBVIE INC. $12,426.70 03/07/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202462150
Principal investigator 1 ABBVIE INC. $1,500.00 02/27/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418497
Principal investigator 1 ABBVIE INC. $1,925.00 02/21/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202453563
Principal investigator 1 Kite Pharma, Inc. $19,710.00 02/19/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069938
Principal investigator 1 BeiGene, Ltd. $3,650.00 02/03/2025 Non-covered Recipient Entity
Novant Health Clinical Research
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190320510
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,950.00 02/03/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496813
Principal investigator 1 Iovance Biotherapeutics, Inc. $650.00 02/03/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496815
Principal investigator 1 Genentech, Inc. $1,038.00 01/28/2025 Non-covered Recipient Entity
PRESBYTERIAN HOSPITAL CANCER CENTER
glofitamab atezo or glofitamab polatuzumab in R R NHL No dispute reported 06/30/2026 1211638833
Principal investigator 1 AstraZeneca UK Limited $627,430.98 01/27/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma No dispute reported 06/30/2026 1185538743
Principal investigator 1 Acerta Pharma LLC $50,533.60 01/23/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185538741
Principal investigator 1 Eli Lilly and Company $103,681.52 01/22/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187873373
Principal investigator 1 Kite Pharma, Inc. $14,150.00 01/22/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1212069934
Principal investigator 1 Genentech, Inc. $870.00 01/21/2025 Non-covered Recipient Entity
PRESBYTERIAN HOSPITAL CANCER CENTER
glofitamab atezo or glofitamab polatuzumab in R R NHL No dispute reported 06/30/2026 1211638829
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,726.00 01/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496817
Principal investigator 1 Iovance Biotherapeutics, Inc. $650.00 01/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496819
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,811.00 01/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496821
Principal investigator 1 Iovance Biotherapeutics, Inc. $390.00 01/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496823
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,600.00 01/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
101623 No dispute reported 06/30/2026 1252496825
Principal investigator 1 Celgene Corporation $184,688.65 01/17/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Phase 2, open-label, single arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 (lisocabtagene maraleucel) in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1222306217
Principal investigator 1 ABBVIE INC. $16,064.56 01/13/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202418493
Principal investigator 1 ABBVIE INC. $86,378.50 01/10/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202437990
Principal investigator 1 Eli Lilly and Company $1,730.20 01/09/2025 Covered Recipient Teaching Hospital
PRESBYTERIAN HOSPITAL HUNTERSVILLE
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187874897
Principal investigator 1 ABBVIE INC. $1,333.80 01/02/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202434840